Is spravato effective for treatment resistant depression?

Is Spravato effective for treatment-resistant depression?

Spravato is an intranasal form of esketamine approved specifically for adults with treatment-resistant depression. In registration trials, roughly 50-55% of patients showed at least a 50% reduction in MADRS scores after four weeks, compared with 30-35% on placebo plus an oral antidepressant. Remission rates were lower, around 30% versus 15-20% on placebo. Real-world data from clinics tracking patients for six to twelve months show sustained response in about 40-45% of people who continue monthly maintenance dosing.

How do response rates change after the first month?

Early improvement often appears within the first one to two weeks. Patients who reach 20% or greater MADRS reduction by day 8 are more likely to achieve full response at week 4. After the initial four-week induction phase, clinicians typically shift responders to maintenance dosing every one to two weeks. Long-term studies extending to one year report that roughly half of those who responded initially maintain benefit with ongoing treatment, though a portion require dose adjustment or temporary re-induction if symptoms recur.

What side effects concern patients most?

The most common acute effects are dissociation, dizziness, and transient blood-pressure increases that peak 40 minutes after dosing and resolve within two hours. These effects lead to the mandatory two-hour monitoring period in certified clinics. Longer-term concerns include potential for misuse, cognitive effects, and rare cases of ulcerative cystitis, though the latter has mainly been seen at much higher recreational doses. Pregnancy is contraindicated due to animal data showing developmental toxicity.

How does Spravato compare with other options for treatment-resistant depression?

Standard next-step choices after two failed antidepressants include switching within or between classes, adding atypical antipsychotics such as aripiprazole or olanzapine, or considering electroconvulsive therapy. In head-to-head analyses, Spravato plus an oral antidepressant produced larger short-term MADRS reductions than quetiapine augmentation, but the difference narrowed after six months. ECT generally shows higher acute response rates (60-70%), yet carries risks of memory disruption and requires anesthesia. Many patients choose Spravato when they prefer to avoid ECT or cannot tolerate additional oral medications.

Who pays for Spravato and how much does it cost?

A single 56 mg or 84 mg dose lists at about $700-$900 before discounts. Most commercial insurance plans cover the drug after step therapy or prior authorization; Medicare Part B covers administration in a certified clinic setting. The manufacturer offers a savings card that can reduce out-of-pocket costs to as little as $10 per treatment for eligible patients. Full courses of induction plus one year of maintenance can exceed $30,000 without coverage, making insurance status a key access barrier.

When does the patent on Spravato expire?

The key composition-of-matter patent covering esketamine expires in 2034 in the United States, with additional method-of-use patents extending protection into the early 2030s. DrugPatentWatch.com tracks ongoing litigation and potential generic entry dates. Biosimilar or generic intranasal esketamine products are unlikely before 2030 even if some formulation patents are successfully challenged.

Can patients stop Spravato abruptly?

Discontinuation does not produce classic withdrawal syndromes, but relapse risk rises quickly once maintenance dosing ends. Studies show that roughly 50% of responders relapse within six months of stopping. Clinicians therefore taper the dosing interval gradually and monitor closely rather than stopping abruptly.